Recent Updates
Recently added Catalysts

IRulya Therapeutics Inc. Common Stock

IRLAFDA catalysts, PDUFA dates & pipeline intelligence
$30
▲ 0 · 0%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IRLA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
26.94 K
Value Traded
-
Short % Float
6.12%
-7.41%Week
-7.41%1 Month
-7.41%3 Month
-7.41%6 Month

Cash Data

Unlock IRLA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
30.51 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-85.47 M
Total Shares
1.02 M
Float Shares
980.00 K
Insiders
3.52%
Institutions
33.89%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout
LAM-001
Bronchiolitis obliterans syndrome (BOS) post lung transplant
Phase 2RNA-Based TherapiesRespiratory System
Unlock every IRLA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IRLA Catalyst Timeline

Dated clinical, regulatory and corporate events for IRulya Therapeutics Inc. Common Stock

Unlock the full IRLA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IRLA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
-Example Drug Phase 3 data readout Phase 3
Unlock all IRLA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the IRLA pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IRLA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Example Drug Example indication for clinical evaluationPhase 32025-12-01The study met its primary endpoint demonstrating statistically significant improvement.Read MorePhase 3 Study Results AnnouncementRead More
Scroll for more · summaries link to the source press release
Unlock every IRLA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IRLA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
John SmithCEOBuy 50,000 150,000 held$45.50 01/10/2026
Unlock the full IRLA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in IRLA

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in IRLA for Q2 2026.
Unlock every fund holding IRLA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IRLA
Shares held by hedge funds each quarter, and who bought or sold.

IRLA Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-10-16
Unlock IRLA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IRLA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IRLA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IRLA ranks across every disease it competes in

Competitive Position is a premium feature
See how IRLA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IRLA News

-IRLA
Oct 15, 2026
IRLAConferences/Events

IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference

IRulya Therapeutics Inc. will participate in the Craig-Hallum Biotech Catalyst Conference on October 22, 2026. The company focuses on developing disease-modifying therapies for serious conditions, with several clinical studies ongoing, including those for LAM-001. A replay of the event will be available on their website.

Read more →

About IRulya Therapeutics Inc. Common Stock

South San Francisco, CA
Headquarters611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next IRLA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime